Polaris Venture Management Co. V, L.L.C. Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
4
Insider Buys Sum
$45.59M
Insider Sells Quantity
13
Insider Sells Sum
$85.94M

Insider Activity of Polaris Venture Management Co. V, L.L.C.

Biography of Polaris Venture Management Co. V, L.L.C.

No biography is available at this moment.

2019-12-17SalePhreesia, Inc.
PHR
10 percent owner
714,242
1.8667%
$24.48$17.48M+13.88%
2019-07-22SalePhreesia, Inc.
PHR
10 percent owner
793,598
8.7688%
$18.00$14.28M+13.72%
2019-07-17SaleCardlytics, Inc.
CDLX
10 percent owner
55,562
0.2345%
$27.45$1.53M+76.85%
2019-07-16SaleCardlytics, Inc.
CDLX
10 percent owner
41,924
0.1793%
$27.87$1.17M+76.17%
2019-07-15SaleCardlytics, Inc.
CDLX
10 percent owner
39,968
0.1701%
$27.73$1.11M+74.5%
2019-06-07SaleCardlytics, Inc.
CDLX
10 percent owner
200,000
0.8717%
$25.62$5.12M+61.33%
2019-06-06SaleCardlytics, Inc.
CDLX
10 percent owner
610
0.0027%
$25.00$15,250+70.29%
2019-06-05SaleCardlytics, Inc.
CDLX
10 percent owner
77,202
0.3378%
$24.86$1.92M+66.83%
2019-06-04SaleCardlytics, Inc.
CDLX
10 percent owner
72,756
0.3204%
$23.28$1.69M+79.02%
2019-05-28SaleCardlytics, Inc.
CDLX
10 percent owner
200,000
0.8607%
$23.04$4.61M+72.4%
2018-09-13SaleCardlytics, Inc.
CDLX
100,000
0.4784%
$25.56$2.56M-24.65%
2018-09-12SaleCardlytics, Inc.
CDLX
200,000
0.9309%
$24.78$4.96M-24.38%
2017-11-20PurchaseX4 Pharmaceuticals, Inc.
XFOR
10 percent owner
1M
33.541%
$10.00$10M-10.41%
2015-02-02SaleOcular Therapeutix, Inc.
OCUL
10 percent owner
1M
4.5025%
$29.50$29.5M-32.31%
2014-04-15PurchaseDaré Bioscience, Inc.
DARE
10 percent owner
2.94M
18.5886%
$7.00$20.59M-11.51%
2013-10-04PurchaseFate Therapeutics, Inc.
FATE
10 percent owner
1.67M
6.8738%
$6.00$10M-9.51%
Total: 16
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.